Roka Bioscience to Co-Present Industry Webinar – Game of Zones: A Practical Guide to Listeria Monitoring and Detection
WARREN, N.J., July 26, 2017 /PRNewswire/ — Roka Bioscience, Inc. (NASDAQ: ROKA), a molecular diagnostics company focused on providing advanced testing solutions for the detection of foodborne pathogens will host and present a free, informative webinar titled “Game of Zones: A Practical Guide to Listeria Monitoring and Detection” with guest speaker Dr. Virginia Deibel from Covance.
The webcast topics will include:
- Demonstrating Listeria control through monitoring – a case study
- Fuzzy attributes of regulatory guidance documents
- Environmental Control Programs- what they are and what they are not
- When is Listeria reasonably likely to occur?
- Data demonstrating how new pathogen testing technology is surpassing the traditional culture
This free webcast will take place live on Thursday, August 3rd at 2:00 PM EDT.
Dr. Virginia Deibel, Director of Microbiology at Covance, will be presenting “Taking the Fuzzy out of Logic” which will provide an example driven guide that can serve as a template for food processors in the development and execution of Listeria monitoring programs.
The webcast will also feature Dr. Evan Chaney, Director of Customer Applications and Microbiology at Roka Bioscience who will present “Trusting the Method”, highlighting recent data that supports adoption of advanced, molecular diagnostics in food safety as they surpass the traditional culture based gold standards.
To register for this free informative podcast click here:
About Roka Bioscience
Roka Bioscience, Inc. is a molecular diagnostics company focused on developing and commercializing advanced testing solutions for the food safety testing market. Our Atlas® Detection Assays incorporate our advanced molecular technologies and are performed on our “sample-in, result out” Atlas System that automates all aspects of molecular diagnostic testing on a single, integrated platform. The Atlas System and Detection Assays are designed to provide our customers with accurate and rapid test results with reduced labor costs and improved laboratory efficiencies. For more information, visit https://www.rokabio.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended (the “Exchange Act”), including those related to our planned service offerings. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. Any statements contained herein (including, without limitation, statements to the effect that we “believe”, “expect”, “anticipate”, “plan” and similar expressions) that are not statements of historical fact should be considered forward-looking statements. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by these forward looking statements. There are a number of important factors that could cause actual results to differ materially from those indicated by such forward-looking statements. Such factors include those set forth in the company’s filings with the Securities and Exchange Commission. We expressly disclaim any obligation to update any forward-looking statements, except as may be required by law. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this press release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this press release.
Investor or Media related inquiries please contact:
Investor Contact:
Roka Bioscience, Inc.
ir@rokabio.com
855-ROKABIO (855-765-2246)
SOURCE Roka Bioscience, Inc.